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1. Introduction
Stem cells are a subset of biological cells in the human body that are capable of 
self-renewal, tissue repair, differentiation, and division into different cell lineages 
[1–3]. Based on their origin and potency, stem cells are divided into either (1) 
embryonic and adult (non-embryonic) stem cells or (2) unipotent, oligopotent, toti-
potent, multipotent, and pluripotent stem cells [1, 2, 4, 5]. Multipotent or adult stem 
cells include mesenchymal stem cells (MSCs), while pluripotent stem cells include 
embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs) [5].
2. MSCs
MSCs are heterogeneous, non-hematopoietic, adult multipotent stromal 
progenitor cells that are capable of self-renewal and differentiation into multiple 
lineages and various cell types [6–12]. They were first described in the 1960s by 
Alexander Friedenstein [7, 8, 10, 13]. They can be isolated from the bone marrow 
(BM), peripheral blood, umbilical cord blood, amniotic fluid, placenta, adipose tis-
sue (AT), dental pulp, palatal tonsil, synovial fluid, salivary glands, as well as liver, 
lung, skin, and skeletal muscle tissues [6–13]. The main source of MSCs is the BM 
although MSCs constitute only a small fraction of the total number of cells populat-
ing the BM [7, 9–11].
MSCs have certain distinguishing features: being plastic adherent and ability of 
differentiation into osteoblasts, adipocytes, and chondrocytes, in addition to having 
characteristic surface markers [6–8, 10, 11, 13, 14]. On flow cytometry, they are 
characteristically positive for CD105, CD73, and CD90 and negative for CD45, CD34, 
CD11b, CD14, CD19, CD79a, and HLA-DR [6–8, 10, 11, 13]. However, several studies 
have shown that MSCs obtained from BM, AT, and other sources do express CD34 
surface markers [9, 15–18]. MSCs can be seen in abundant numbers in the circula-
tion under the following circumstances: stem cell mobilization with growth factors, 
tissue injuries, stroke, hypoxia, and inflammatory conditions [9, 19–24]. Despite 
the efforts made over the last five decades including identification of nine transcrip-
tional factors, little is known about the molecular basis underlying the stemness of 
MSCs, and it is still unclear whether the recently discovered genes regulate stemness 
or only differentiation of MSCs [12].
MSCs have immunomodulatory and immunosuppressive properties that enable 
them to have several therapeutic and clinical applications, which include the 
enhancement of engraftment as well as prevention and treatment of graft versus 
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host disease (GVHD) in recipients of allogeneic hematopoietic stem cell transplan-
tation (HSCT); treatment of several autoimmune disorders such as systemic lupus 
erythematosus, rheumatoid arthritis, systemic sclerosis, type I diabetes mellitus, 
and Crohn’s disease; role in regenerative medicine and tissue repair including 
treatment of myocardial ischemia, myocardial infarction, cardiac dysfunction, 
dilated cardiomyopathy, chronic non-healing wounds, critical limb ischemia, liver 
injury, spinal cord injuries, as well as macular degeneration, corneal reconstruc-
tion, and transplantation; neurological disorders such as multiple sclerosis and 
amyotrophic lateral sclerosis; bone and cartilage diseases such as osteogenesis 
imperfecta; and treatment of various infections and acute respiratory distress 
syndrome [6, 7, 11, 25–27].
MSCs are major constituents of hematopoietic stem cell niche which is a highly 
complex and dynamic microenvironment of the BM [28]. Leptin receptor (LepR) is 
a marker that enriches BM-MSCs, and LepR+ cells in the BM are a major source of 
bone, cartilage, and adipocytes [29]. The exosome secretome of BM-MSCs regu-
lates stem cell maintenance and their regenerative potential, and this BM-derived 
secretome will be critical to the future development of therapeutic strategies for 
oncologic diseases and regenerative medicine [30]. Apparently, MSCs are the 
masters of survival and clonality as they communicate with diverse immune cells 
and interact with other cellular components of the BM microenvironment as well as 
with normal cells, leukemic stem cells, and progenitor cells [31]. The main func-
tions of MSCs include formation of hematopoietic microenvironment, modulation 
of the activity of the immune system, and regulating cell trafficking [32]. When 
stimulated by specific signals, MSCs can be released from BM niche into circulation 
and can be recruited to the target tissues where they undergo in situ differentiation 
and contribute to tissue regeneration and homeostasis [33]. The efficacy of MSCs is 
linked to their immunosuppressive and anti-inflammatory properties primarily due 
to the release of soluble factors [34].
The putative roles of BM-MSCs during infection are detection of pathogens; 
activation of host immune response; elimination of pathogens; induction of proin-
flammatory gradients; and modulation of proinflammatory host immune response 
[6, 7]. Examples of the immunoregulatory properties of MSCs include inhibition of 
differentiation of monocytes to dendritic cells (DCs), alteration of cytokine profile 
of DCs, induction of tolerant phenotypes of naïve and effector T cells, inhibition of 
antibody production by B cells, and suppression of natural killer (NK) cell prolif-
eration and NK-mediated cytotoxicity [35]. BM-MSCs may augment antimicrobial 
responses, abridge proinflammatory and damage responses, and ameliorate injury 
caused by the host defense to the pathogen [6, 7]. BM-MSCs appear to function 
as a critical fulcrum providing balance by promoting pathogen clearance during 
the initial inflammatory response and suppressing inflammation to preserve host 
integrity and facilitate tissue repair [6].
MSCs could potentially be involved at multiple levels in host defense by mobiliz-
ing immune effector cells and modulation of proinflammatory immune responses 
so as to minimize the tissue damage induced by inflammation [6, 36]. The immu-
nomodulatory properties of MSCs are mediated by both: cell to cell interaction and 
the secreted cytokines [36, 37]. BM-MSCs may protect against infectious challenge 
either by direct effects on the pathogens or through indirect effects on the host [6]. 
On the other hand, certain types of MSCs, particularly placenta-derived MSCs and 
fetal membrane-derived MSCs, are highly susceptible to herpes viruses including 
varicella zoster virus [7, 38].
Studies have shown that several types of stem cells including BM-MSCs and 
neural stem cells can cross the blood brain barrier and reach tumors localized in 
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the brain such as glioblastoma multiforme as well as ischemic areas and injured 
sites in the brain and engraft there. Hence, MSCs can be used as means of cellular 
carriers or Trojan horses to deliver cytotoxic genes or therapeutic agents for brain 
tumors, and they can be used to exert their therapeutic and regenerative effects 
in the brain [39–43]. In cancer, MSCs are a double-edged sword as they can exert 
stimulatory effects on tumor development, while they can have inhibitory effects 
on cancer cell growth and metastases [44]. MSCs have anticancer properties, and 
they can be engineered or modified to become carriers of suicide genes, employed 
as carriers of anti-angiogenesis factors, and utilized to target cancer stem cells 
[45–47]. MSCs have recently been engineered to express antiproliferative, anti-
apoptotic, and antiangiogenic agents that specifically target different types of solid 
tumors [45].
The capacity of MSCs to proliferate and differentiate into other cells in addi-
tion to their ability to release biomolecules such as cytokines, growth factors, and 
microvesicles that have anti-inflammatory, immunomodulatory, anti-fibrogenic, 
and trophic functions make MSCs ideal candidates to function as delivery platform 
for cellular and gene therapies [48, 49]. Consequently, clinical trials incorporating 
the utilization of MSCs in the treatment of immune-related diseases have rapidly 
evolved after reports from preclinical studies confirming their safety and efficacy 
[49]. Recently, scientists have established several strategies to generate highly 
functional AT-derived MSCs and these include preconditioning of AT-MSCs with 
various stimulants and inflammatory agents; genetic manipulation of AT-MSCs; 
modification of culture conditions with three-dimensional aggregate formation 
and hypoxic culture; and proper utilization of exosome and extracellular vesicles 
(ECVs) that are secreted by AT-MSCs [50, 51]. Also, the main focus has recently 
shifted from studying differentiation of MSCs to studying their paracrine proper-
ties such as the release of ECVs that contain numerous micro-RNAs (miRNAs) 
including regulatory miRNAs and the production of multiple bioactive proteins and 
compounds that regulate MSC differentiation [52]. Hence, soluble elements derived 
from MSCs including ECVs have recently been proposed as a cell-free alternative for 
various therapies on the clinical side [51].
The combination of MSCs and tissue engineering technology can enhance the 
immunoregulatory properties of MSCs, and this will ultimately lead to further 
expansion of their utilization in regenerative medicine [53]. Tissue engineering 
strategies such as the use of various types of stem cells, scaffolds, medical devices, 
gene therapy, and nanotopography have resulted in progressing the translation 
of basic research towards clinical therapeutics [54, 55]. Despite the remarkable 
progress in MSC therapies, sufficient data on the biodistribution of MSCs, cellular 
and molecular structures of their target cells, and mechanisms by which MSCs 
reach these targets are still lacking [56]. Also, several obstacles need to be overcome 
before the utilization of specific types of MSCs in tissue engineering becomes a 
routine practice in the clinical arena [57]. Currently, human MSCs are generated 
through conventional static adherent cultures in the presence of fetal bovine serum 
or human-sourced supplements. Unfortunately, these methods are not ideal proce-
dures to meet the future expectations of quality-assured human MSCs for clinical 
therapies in humans [58]. Additionally, having substantial gaps in our knowledge 
of the biology and therapeutic efficacy of MSCs presents major challenge to their 
sustainable implementation in clinical medicine [59]. Thus, optimizing the biopro-
cess to generate human MSCs and their products will improve efficacy and safety 
of stem cell therapies [58]. Also, improving the cultural environment of MSCs and 
selecting the appropriate scaffolds and induction factors are essential in improving 
the outcome of MSC-based tissue engineering [60].
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3. iPSCs
Human iPSCs resemble human ESCs in many aspects including morphol-
ogy, proliferation, differentiation potential, and pluripotency markers, but 
the epigenetic characteristics of human iPSCs are rather distinct [1, 2, 5, 61]. 
Although the utilization of iPSCs can avoid the obstacles and ethical concerns 
that limit the use of human ESCs, clinical application of human iPSCs still has a 
number of disadvantages that include chromosomal instability and tumorigenic 
potential, thus raising questions about the safety of their clinical utilization, and 
low reprogramming efficiency in addition to other concerns about their repro-
ducibility for laboratory applications in disease modelling and drug screening 
[1, 3, 5, 61, 62].
In 2006, Takahashi and Yamanaka were the first scientists to generate mouse 
iPSCs from dermal fibroblasts through retroviral-mediated ectopic expression of 
the four genes: OCT4, SOX2, KLF4, and c-MYC [1, 3, 4, 63]. Since this discovery, 
iPSCs have been used in many research and clinical trials, including disease model-
ling; drug toxicity as well as drug discovery; and regenerative medicine [3–5]. 
Reprogramming of iPSCs should have the following crucial requirements: species 
such as human or mouse; cell type such as blood cell or fibroblast; factor, drug, 
chemical, or other protein molecules such as miRNA, DNA modifying agent, 
NANOG, or LIN28; vector such as retrovirus or lentivirus; and disease with specific 
genetic mutation [1, 4, 5, 64].
Human iPSCs have revolutionized the field of human disease modelling with an 
enormous potential to serve as paradigm shifting platforms for preclinical trials, 
personalized clinical diagnosis, and personalized drug therapy [65]. During the last 
13 years, significant developments and remarkable progress have been achieved 
in enhancing reprogramming techniques and their efficacy, increasing safety of 
derived iPSCs, and developing different delivery methods [61, 62]. The ability 
to generate iPSCs from human somatic cells provides tremendous promises and 
opportunities in basic research and regenerative medicine and can provide a wide 
range of applications including cell-based therapies, drug screening, and disease 
modelling [61, 66].
The capacity of human iPSCs to retain patient-specific genomic, transcriptomic, 
proteomic, metabolomic, and other visualized big data information makes it pos-
sible to extend their applications beyond disease modelling into the field of person-
alized medicine which encompasses the adoption of novel prevention and treatment 
strategies based on individual variability [65]. The emergence of modern iPSC tech-
nology, with the capacity of these stem cells to undergo unlimited self-renewal and 
differentiation into any type of cell, has a great potential to advance translational 
applications including stem cell therapies and the generation of large-scale collec-
tions of cell lines for research purposes [67]. Recently, genomic editing technolo-
gies have been applied to correct the mutations in disease-specific iPSCs to create 
gene-corrected iPSCs that can be utilized in autologous stem cell-based therapies 
[64]. Nowadays, patient-specific iPSCs can be obtained by reprogramming of adult 
somatic cells by ectopic expression of pluripotency-associated transcription factors 
including OCT4, SOX2, KLF4, and c-MYC [64]. The availability of precisely gener-
ated iPSC-derived functional cells to replace or repair damaged tissues or organs 
will likely affect therapies of hematopoietic disorders and facilitate treatment of 
neurological, cardiovascular, hepatic, and retinal diseases and possibly diabetes 
mellitus [67]. Additionally, patient-specific iPSCs can bypass certain limitations of 
ESCs such as ethical concerns and immunological rejection [64]. The first clinical 
trial on cell-based therapy using iPSCs derived from patients to treat blindness 
started in Japan in September 2014 [67].
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4. iPSC-MSCs and conclusion
MSCs derived from iPSCs (iPSC-MSCs) exhibit higher proliferation rate and less 
senescence than BM-MSCs, and thus the former cells are emerging as an attractive 
therapeutic option for obtaining a substantial population of stem cells in a sustained 
manner for applications in regenerative medicine [68, 69]. Several studies using 
human iPSC-MSCs and their exosomes in human and animal studies have shown 
that transplantation of these cells can produce protection of the liver against hepatic 
ischemia; reduction in the volume of brain infarction and preservation of neuro-
logical function after acute intracranial hemorrhage; prevention of osteonecrosis 
of femoral head by promotion of local angiogenesis and prevention of bone loss; 
facilitation of cutaneous wound healing by promotion of collagen synthesis and 
angiogenesis; and modulation of differentiation and function of DCs in order to 
support their clinical application in DC-mediated immune disorders [69–73]. Thus, 
MSCs and iPSCs may reshape the future of medical therapeutics and may eventu-
ally become curative for several chronic and intractable medical illnesses [2, 4, 5].
© 2020 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
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